Integrin β₁-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH

Hepatic recruitment of monocyte-derived macrophages (MoMFs) contributes to the inflammatory response in non-alcoholic steatohepatitis (NASH). However, how hepatocyte lipotoxicity promotes MoMF inflammation is unclear. Here we demonstrate that lipotoxic hepatocyte-derived extracellular vesicles (LPC-EVs) are enriched with active integrin β₁ (ITGβ₁), which promotes monocyte adhesion and liver inflammation in murine NASH.

Hepatocytes were treated with either vehicle or the toxic lipid mediator lysophosphatidylcholine (LPC); EVs were isolated from the conditioned media and subjected to proteomic analysis. C57BL/6J mice were fed a diet rich in fat, fructose, and cholesterol (FFC) to induce NASH. Mice were treated with anti-ITGβ₁ neutralizing antibody (ITGβ₁Ab) or control IgG isotype.

Ingenuity® Pathway Analysis of the LPC-EV proteome indicated that ITG signaling is an overrepresented canonical pathway. Immunogold electron microscopy and nanoscale flow cytometry confirmed that LPC-EVs were enriched with activated ITGβ₁. Furthermore, we showed that LPC treatment in hepatocytes activates ITGβ₁ and mediates its endocytic trafficking and sorting into EVs. LPC-EVs enhanced monocyte adhesion to liver sinusoidal cells, as observed by shear stress adhesion assay. This adhesion was attenuated in the presence of ITGβ₁Ab. FFC-fed, ITGβ₁Ab-treated mice displayed reduced inflammation, defined by decreased hepatic infiltration and activation of proinflammatory MoMFs, as assessed by immunohistochemistry, mRNA expression, and flow cytometry. Likewise, mass cytometry by time-of-flight on intrahepatic leukocytes showed that ITGβ₁Ab reduced levels of infiltrating proinflammatory monocytes. Furthermore, ITGβ₁Ab treatment significantly ameliorated liver injury and fibrosis.

Lipotoxic EVs mediate monocyte adhesion to LSECs mainly through an ITGβ₁-dependent mechanism. ITGβ₁Ab ameliorates diet-induced NASH in mice by reducing MoMF-driven inflammation, suggesting that blocking ITGβ₁ is a potential anti-inflammatory therapeutic strategy in human NASH.

Herein, we report that a cell adhesion molecule termed integrin β₁ (ITGβ₁) plays a key role in the progression of non-alcoholic steatohepatitis (NASH). ITGβ₁ is released from hepatocytes under lipotoxic stress as a cargo of extracellular vesicles, and mediates monocyte adhesion to liver sinusoidal endothelial cells, which is an essential step in hepatic inflammation. In a mouse model of NASH, blocking ITGβ₁ reduces liver inflammation, injury and fibrosis. Hence, ITGβ₁ inhibition may serve as a new therapeutic strategy for NASH.